is called the (https://ghr.nlm.nih.gov/gene/TP53) "Guardian of the Genome" due to its ability to protect cells from accumulating cancer causing mutations.
We also previously reported that TP53
mutations can be detected in the plasma of most metastatic TNBC patients (11).
Doctors at Dana-Farber are now working on new strategies to overcome the challenges posed by TP53
mutations in MDS.
Quantitative PCR was performed to confirm expression changes of proteins with highest connectivity, including EGFR, TP53
, HSPA5, excision repair cross-complementation group 1 (ERCC1), and X-ray repair cross complementing 1 (XRCC1), in several prostate cell lines.
Mutation of TP53
gene was demonstrated by Sanger sequencing.
Our standard molecular sequencing panel was performed on the tumor tissue and additionally identified a TP53
c.817C>T (p.R273C) mutation.
It included genes for apoptosis (Tp53
, TP53INP2, and DFFA), antiapoptosis (BCL2), cell proliferation (E2F3 and Ki67), and cell differentiation (SOX2) (Figure 2).
Moreover, we demonstrated that Dioscin displayed anticancer activity via up-regulating expression of TP53
, BAX and CASP3 protein, as well as down-regulating BCL2 in Bel-7402 cells.
More gene copies mean fewer cancer deaths Elephants Humans Cancer death rate 4.8% 11 to 25% Copies of TP53
gene ~20 1 SOURCE: L.M.
K-ras proto-oncogene and TP53
tumour suppressor gene mutations are among the most common genetic alterations in advanced colorectal tumours.
Caused by mutations in the tumor suppressor gene TP53
, individuals with the syndrome have a 90% risk of cancer by age 60 years.
Background: Tumour suppressor genes such as TP53
, BRCA1 and RAD51 are involved in DNA repair and their malfunctions result in genomic instability and cancer.